Ziekenhuis Oost-Limburg

zol.be

Total trials

67

Active

22

Phase 3

1

Total enrollment

14,063

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 11 of 11 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Sacubitril-valsartan1
Standard of care1
Dexamethasone1
Down-titration1
Continuation of guideline-directed heart failure therapy1
Dexmedetomidine1
Ferric Carboxymaltose1
Sodium Chloride (NaCl) 0.9 %1
0.25% ropivacaine1
0.5% ropivacaine1
1% ropivacaine1

Next readouts

  • 2025-09-22
  • 2026-04-01
  • 2027-02
  • 2027-05-01
  • 2028-07
  • 2028-09

Top conditions

  • Atrial Fibrillation5
  • Heart Failure3
  • NAFLD3
  • Acute Kidney Injury2
  • Fatty Liver, Nonalcoholic2
  • Preterm Birth2
  • Anesthesia2
  • Surgery2

Frequently asked questions about Ziekenhuis Oost-Limburg

How many clinical trials does Ziekenhuis Oost-Limburg have on ClinicalTrials.gov?
Ziekenhuis Oost-Limburg is listed as the lead sponsor on 67 clinical trials in ClinicalTrials.gov, 22 of which are currently active (recruiting, enrolling, or ongoing).
How many of Ziekenhuis Oost-Limburg's trials are in Phase 3?
1 of Ziekenhuis Oost-Limburg's trials are in Phase 3, spread across 11 active drug programs.
What therapeutic areas does Ziekenhuis Oost-Limburg focus on?
Ziekenhuis Oost-Limburg's most-studied conditions on ClinicalTrials.gov are Atrial Fibrillation, Heart Failure, NAFLD, Acute Kidney Injury, Fatty Liver, Nonalcoholic.
When are Ziekenhuis Oost-Limburg's next clinical trial readouts?
Ziekenhuis Oost-Limburg has 6 upcoming primary-completion readouts tracked here; the soonest is “Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation”, expected around 2025-09-22.